Answers are grounded in this paper and cite their sources.
Objectives To determine the macular vascular and structural changes in diabetic macular edema (DME) in response to intravitreal ranibizumab versus aflibercept as detected by optical coherence tomography, and optical coherence tomography angiography. Patients and methods A prospective, comparative study was conducted on 100 patients with DME divided equally into two groups: ranibizumab group which was treated with intravitreal injection of ranibizumab, and aflibercept group which was treated by intravitreal injection of aflibercept. Each patient received an injection monthly for 3 months. Full ocular examination and optical coherence tomography angiography imaging were performed for all patients. Results Both ranibizumab and aflibercept groups showed a significant reduction in both superficial and deep foveal and parafoveal vessel density ( P <0.05) after third injection. Both groups showed a nonsignificant change in superficial capillary plexus foveal avascular zone (FAZ), but a significant decrease in deep capillary plexus (DCP) FAZ after three injections. There was a significant decrease in central macular thickness (CMT), and a significant increase in best corrected visual acuity after treatment in both groups. There was a nonsignificant difference between both groups as regard all parameters assessed in the study. Post-third injection, inferior and temporal parafoveal deep vessel density, DCP FAZ, and CMT were significantly lower in responders than nonresponders. There was a significant negative correlation between both CMT, DCP FAZ area on one hand, and best corrected visual acuity on the other. No correlation between VD and CMT changes, but a significant positive correlation was detected between CMT and DCP FAZ area. Conclusions Both ranibizumab and aflibercept appear to offer comparable efficacy in treatment of DME. They reduced CMT, improved vision, reduced macular ischemia so decreased DCP FAZ area. No statistically significant superiority of either agent.
No takes yet. Share an insight, caveat, or question.
Abosabah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: